The influence of cardiovascular physiology on dose/pharmacokinetic and pharmacokinetic/pharmacodynamic relationships.

Clinical Pharmacokinetics
Pietro FagiolinoMarta Vázquez

Abstract

Inter- and intraindividual variability in the relationship between dose and clinical--or pharmacodynamic--response of a drug can be analysed in two steps: firstly, by considering the plasma pharmacokinetic response to a given dose and, secondly, by the connection between both pharmacokinetic and pharmacodynamic responses. As the cardiovascular system is the means of transport of endogenous and exogenous substances, blood flow fraction destined to each organ determines the relative mass of solute in plasma, which is constantly in contact with the tissue. Hence, not only the rate but also the extent of drug transfer would be increased when tissues are irrigated by a higher fraction of cardiac output. Aging and circadian rhythms present similar cardiac output distribution patterns when moving from young to aged adult and from nocturnal to diurnal hours. These two changes lead to an increased blood flow delivery to the extra-splanchnic-renal region in the elderly and in the morning, but with a decreased cardiac output in aged individuals and an increased one during the day. This scenario allows us to forecast substance concentrations outside the blood vessels, which are responsible for the extent of drug elimination and the intensi...Continue Reading

References

Jan 1, 1991·European Journal of Clinical Pharmacology·B LemmerH J Becker
Jul 1, 1990·Clinical Pharmacokinetics·M A van Baak
Jul 1, 1989·Journal of Cardiovascular Pharmacology·T Jogestrand, K Andersson
Jul 1, 1989·Clinical Science·M G KoopmanL Arisz
Jul 1, 1985·Clinical Pharmacology and Therapeutics·M V St-PierreS M MacLeod
Aug 1, 1974·Journal of Pharmaceutical Sciences·V P Shah, S Riegelman
Jan 1, 1984·European Journal of Clinical Pharmacology·T Joreteg, T Jogestrand
Jan 1, 1983·European Journal of Clinical Pharmacology·T Joreteg, T Jogestrand
Mar 1, 1982·Clinical Pharmacology and Therapeutics·D D Tang-LiuS Riegelman
Aug 1, 1982·Journal of Pharmacokinetics and Biopharmaceutics·D D Tang-LiuS Riegelman
Jan 1, 1981·European Journal of Clinical Pharmacology·R NewtonI D Bradbrook
Apr 1, 1995·Cardiovascular Research·T A SchmidtK Kjeldsen
Jan 1, 1993·European Journal of Drug Metabolism and Pharmacokinetics·J L SteimerJ Van Bree
Aug 1, 1995·Journal of Clinical Pharmacology·K M SowinskiD J Kazierad
Mar 27, 1998·Clinical Pharmacokinetics·H G Eichler, M Müller
May 21, 1998·Clinical Pharmacokinetics·D G Le Couteur, A J McLean
Jul 23, 1998·Clinical Pharmacokinetics·A HämmerleinD T Lowenthal
Sep 18, 1998·Clinical Pharmacokinetics·B Bruguerolle
Nov 26, 1998·Drugs & Aging·K Turnheim
Apr 20, 2000·The Annals of Pharmacotherapy·T MiuraY Suzuki
Jun 13, 2000·Therapeutic Drug Monitoring·N BleyzacP Maire
Feb 24, 2001·Drugs & Aging·C G HanrattyA P Passmore
Jun 18, 2002·European Journal of Drug Metabolism and Pharmacokinetics·Pietro Fagiolino
Dec 28, 2002·The American Journal of Geriatric Cardiology·Melvin D Cheitlin
Jul 25, 2003·European Journal of Drug Metabolism and Pharmacokinetics·P FagiolinoM Vázquez
Aug 12, 2003·Clinical Pharmacokinetics·Megan A Gibbs, Natilie A Hosea
Aug 14, 2003·Experimental Gerontology·Klaus Turnheim
Nov 20, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Laurence S Kaminsky, Qing-Yu Zhang
May 21, 2004·European Journal of Drug Metabolism and Pharmacokinetics·Pietro Fagiolino
Jun 1, 2004·Pharmacological Reviews·Allan J McLean, David G Le Couteur
Nov 19, 2004·Fundamental & Clinical Pharmacology·Kari T KivistöMartin F Fromm
Jan 7, 2005·Clinical Pharmacokinetics·Monette M CotreauDavid J Greenblatt
Jan 20, 2005·Clinical Pharmacokinetics·David G Le CouteurAllan J McLean

❮ Previous
Next ❯

Citations

Oct 22, 2008·International Archives of Occupational and Environmental Health·Tomicic Catherine, Droz Pierre-Olivier
Aug 21, 2007·Journal of Pharmaceutical Sciences·Bernard BruguerolleNicolas Simon
Feb 6, 2008·Expert Opinion on Drug Metabolism & Toxicology·Massimo Baraldo
Feb 14, 2013·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Pietro FagiolinoRosa Eiraldi
Jan 25, 2011·Journal of Clinical Pharmacology·Henry Tao Peng, Bob Cheung
Dec 2, 2009·Clinical Nursing Research·Lea Ann Matura
Oct 18, 2020·Drugs in R&D·Manuel IbarraPietro Fagiolino
May 1, 2021·BioMed Research International·Martín UmpiérrezCecilia Maldonado

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Risk Reduction

Prevention of cardiovascular disease is an important health initiative. Risk reduction including physical activity, smoking cessation, diet, blood pressure lowering drugs and pharmacotherapy. Here is the latest research on cardiovascular risk reduction.